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Abstract: The canine heartworm, Dirofilaria immitis, is among the most important parasites of
dogs in the United States and worldwide, and may cause severe and potentially fatal disease.
Current diagnostic recommendations rely on serological detection of an adult female antigen, and
visualization of microfilariae in the blood. Therefore, a reliable diagnosis can be only performed
approximately six months post-infection. There is a growing need to characterize novel diagnostic
markers that are capable of detecting the early stages of heartworm infection, in special markers
associated with third-stage larvae (L3) and fourth-stage larvae (L4). The early detection of infection
would guide medical interventions that could impede the development of patent infections and
further parasite transmission. We cultured D. immitis L3 and L4 of two laboratorial strains with
different susceptibility statuses to macrocyclic lactone drugs in vitro. Excretory/secretory microRNAs
were sequenced and analyzed. We identified two miRNA novel candidates secreted abundantly by
both L3 and L4 of both strains. These candidates were previously detected in the secretions of other
D. immitis stages and one of them was found in the blood of D. immitis-infected dogs. These miRNAs
have not been found in the secretions of other nematodes and could be D. immitis-specific diagnostic
biomarkers, which could allow for the early detection of infection.
Keywords: diagnostic biomarkers; Dirofilaria immitis; heartworm; microRNA; early diagnosis; drug
resistance; macrocyclic lactones; ivermectin
1. Introduction
The canine heartworm, Dirofilaria immitis, is arguably the most important parasite
of dogs in the United States of America (USA) and across many countries worldwide.
Heartworm is known to cause severe and often fatal disease in infected dogs, cats, and
ferrets [1,2]. In addition to being the most prevalent filarial parasite of dogs in the country,
heartworm incidence has been increasing in recent years, particularly in the southeastern
United States [3].
The current guidelines of the American Heartworm Society recommend annual testing
of all dogs in order to ensure the achievement and maintenance of successful prophylaxis.
This recommendation includes the concurrent use of both an antigen detection test and a
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microscopy-based microfilariae (mf) detection test [4]. Currently, commercially available
immunodiagnostic assays for the detection of heartworm antigens are used widely by
practicing veterinarians and diagnostic laboratories. Such antigen detection tests target
proteins secreted by mature adult D. immitis females. Despite their high sensitivity and
specificity [4,5], a diagnosis can be only achieved approximately six months post-infection,
which coincides with the average pre-patent period of heartworm.
There is a growing need to explore and characterize novel heartworm biomarkers
that are capable of detecting the early stages of infection, that is, infections that are less
than six months old. Earlier infections can be characterized by the presence of third-stage
larvae (L3) and fourth-stage larvae (L4) and/or young adults (L5) within the organism of a
definitive host, and the absence of sexually mature adult female and male worms in the
hosts’ pulmonary arteries [6]. An early diagnosis of heartworm infection in conjunction
with appropriate clinical management could be beneficial for the health and wellbeing of
the infected individual and beyond by impeding the development of patent infections. As
a consequence, fewer dogs would become reservoirs for infection of suitable Culicidae
mosquito vectors, impacting heartworm transmission at a local scale. In addition, dogs
would be less likely to progress into severe and/or fatal clinical heartworm disease.
Helminth parasites, particularly, have evolved sophisticated mechanisms of commu-
nication with their hosts. Various molecules secreted or excreted by helminths have been
shown to participate in these processes [7,8]. Among them are microRNAs (miRNAs),
short non-coding RNA molecules of 18–25 nucleotides in length, with important post-
transcriptional regulatory functions of gene expression. The presence and detectability of
nematode-specific miRNAs in hosts’ biofluids make them attractive diagnostic biomarker
candidates for a wide range of diseases, and require minimal invasion [9]. To date, a
handful of studies described the secreted miRNA profiles of various filarial nematodes,
including D. immitis [9–13]. Such parasitic nematode-derived miRNAs have been found
circulating in biological fluids (e.g., serum, plasma) and tissues of naturally infected hosts.
The acknowledged presence of specific parasitic nematode-derived miRNAs in host serum
and plasma highlights their potential as biomarkers of infection by filarioid species of
veterinary and public health relevance [14,15].
Previously, D. immitis-derived miRNAs have been characterized in the plasma of dogs
with patent experimental infections (therefore, with the concomitant presence of mf and
adults) [9]. In addition, it was shown that some D. immitis-derived secretory miRNAs are
differentially expressed across developmental stages or sexes of adults, highlighting their
potential as markers for detecting the early stages of heartworm infection [16]. Additionally,
nematode-derived miRNAs have been detected in the blood of animals and humans
infected with tissue-dwelling filarial nematodes such as Onchocerca volvulus, O. ochengi,
and Loa loa, which, similarly to D. immitis L3 and L4, do not reside in the circulatory
system [10,12,17].
In order to assess the potential of D. immitis-derived miRNAs as diagnostic candidates
in vivo, various elements remain to be clarified. In this study, we aimed to assess whether
selected D. immitis L3 and/or L4-derived miRNAs in vitro may be biomarker candidates
for the early detection of infection, both in terms of abundance and species specificity,
as well as the consistency of stage-specific miRNA secretion across replicates and D.
immitis laboratorial strains with different susceptibilities to macrocyclic lactone drugs. We
compared our results to the existing literature and identified two novel miRNA candidates
secreted abundantly by both L3 and L4 developmental stages and in both strains.
2. Results
2.1. Libraries and General Results
Six samples from each strain, Yazoo (resistant to macrocyclic lactones) and Missouri
(susceptible to macrocyclic lactones) were analyzed, encompassing three replicates from
L3, and three from L4. Libraries contained between 5.49 and 10.86 million reads. Across
all samples (i.e., strains and stages), a total of 187 unique mature miRNAs with different
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degrees of confidence were discovered (Supplementary Table S1). For the subsequent
analyses, we stratified the data by strain and/or stage (Supplementary Tables S2–S5).
2.2. Strain and Stage Specificity
We considered all miRNA candidates for our initial analysis, including those with no
known orthologues among nematode sequences available in miRBase. We identified a total
of 187 mature miRNA sequences across all six samples (Supplementary Table S1). The level
of agreement between both strains and the two stages was high. Several members of the
miR-100 family were among the top 10 most abundantly represented sequences, as well as
lin-4 and let-7 (Table 1). Bma-miR-81, bma-miR-57, and bma-miR-92 were also among the
highly abundant sequences present in all samples (if not among the top 10).
Differential expression analysis was performed, taking all miRNAs into account ex-
pressed in at least one sample (Figure 1). One single miRNA (bma-miR-87a_R+1) was
consistently found in L4 sample replicates in low levels (between 11 and 15 copies, nor-
malized counts), but not in L3 samples of the strain Yazoo. The trend was similar in the
strain Missouri, but the expression in both examined stages was not significantly different.
bma-miR-87a_R+1 was always present in L4 secretions, found between 5 and 60 copies,
and between 0 (in 2 samples) and 9 copies in L3 samples (Missouri, normalized counts).
One miRNA (bma-miR-228) was found to be more abundant in Missouri than in Yazoo
L3 products (normalized counts; Figure 1); it was, however, present in all replicates of
both stages. Similarly, PC-5p-7293_584 was present in all samples and replicates were in
high amounts and detected in slightly higher copy numbers in Missouri than in Yazoo
L4 supernatants.
There were 2 predicted candidates (PC-5p-7293_584 and PC-3p-5433_825) that were
also highly and consistently represented in all 4 samples (L3s and L4s of both strains) and
are among the 20 most abundant miRNAs. These miRNAs map to the D. immitis genome
but have no described orthologues among the available nematode miRNAs in miRBase
v21. Hence, these might represent miRNAs specific to D. immitis. PC-5p-7293_584 was
the 7th and 9th most abundant miRNA in L3 supernatants from the Yazoo and Missouri
strains, respectively (191 and 393 copies), while it ranked 15th and 16th most abundant in
L4 secretions, from the Yazoo and Missouri strains, respectively (>100 copies).
PC-3p-5433_825 was the 9th and 13th most abundant miRNA in L3 supernatants
from the Yazoo and Missouri strains (>100 copies), respectively, while it ranked 10th and
12th most abundant in L4 from the Yazoo and Missouri strains, respectively (>200 copies);
details are available in Supplementary Tables S2–S5.
2.3. Comparison to Previous Reports
At the sequence level, and taking all miRNAs into account regardless of the confidence
status, 26 miRNAs were common to L3 secretions from the current study and an initial
prior study conducted in vitro [16]. Similarly, 39 sequences were found in cultures from L4s
in both studies, with both strains combined (Figure 2). In miRNA discovery experiments, it
is likely that a fraction of predicted candidate sequences do not correspond to real miRNAs
but rather to artifacts; therefore, these numbers must be interpreted with caution. Despite
the fact that the same species and stages were examined in the compared studies, only
a small fraction of miRNA sequences overlapped. Here, whole mature sequences were
considered, despite the fact that the 3′ end of mature sequences are known to be subject to
variation [18].
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Table 1. Top 10 most abundant miRNAs. The ranking was established based on differential expression analysis for Yazoo and Missouri separately.
Top 10 Most Abundant miRNAs Previous Study [16]
Yazoo L3 Missouri L3 Yazoo L4 Missouri L4 L3 L4
1 bma-miR-100a_R+1 ** bma-miR-100a_R+1 ** bma-miR-100a_R+1 ** bma-miR-100a_R+1 ** bma-lin-4 bma-lin-4
2 bma-miR-100b_R+2 * bma-miR-100b_R+2 * bma-lin-4 * bma-lin-4 ** PC-3p-389_2939 bma-miR-92_R+2
3 bma-lin-4 * bma-lin-4 * bma-miR-100b_R+2 * bma-miR-100b_R+2 * asu-let-7-5p asu-let-7-5p
4 bma-miR-100d_R+1 * bma-miR-100d_R+1 * bma-miR-100d_R+1 * bma-miR-100d_R+1 * bma-miR-100b_R+1 bma-miR-100a_R+1











bma-miR-57 bma-miR-92_R+2 bma-miR-100d_R+1 bma-miR-100d_R+1




9 PC-3p-5433_825 PC-5p-7293_584 asu-let-7-5p bma-miR-239-5p bma-miR-228 bma-miR-5364
10 bma-miR-81_R+1 bma-miR-7_R+1_1ss10TA PC-3p-5433_825 bma-miR-71_R+4 hco-miR-9
bma-bantam_R+1
(= bma-miR-81_R+1)
** present in >10,000 copies (normalized counts); * present in >1000 copies (normalized counts). ‘Predicted candidates’ of interest are bolded.
Pathogens 2021, 10, 786 5 of 13
Figure 1. The number of differentially expressed miRNAs across pairwise comparisons. The differential expression was
stratified by stages and strain. (A) Differentially expressed miRNAs between stages. For the Yazoo strain, bma-miR-87a_R+1
was absent in L3 secretions (hence, no fold-change). In the Missouri strain, asu-let-7-5p was more abundant in L3 compared
to L4, and two sequences were less abundant in L3 compared to L4 (bma-miR-5866 and hpo-miR-10078-5p_1ss10TC).
(B) Differentially expressed miRNAs between D. immitis strains. Bma-miR-228 was less abundant in Yazoo L3 (resistant to
macrocyclic lactones) compared to Missouri L3 (susceptible to macrocyclic lactones); PC-5p-7293_584 was less abundant
in Yazoo L4 compared to Missouri L4. * indicates ‘low confidence’ sequences, requiring validation. Log2 FC = log2 fold
change in pairwise comparisons. All are statistically significant with a set p-value < 0.05.
A very similar miRNA ranking by abundance had been shown in the supernatants of
cultured L3 and L4, especially when extended beyond the top 10 shown in Table 1 [16]. A
sequence similar to PC-5p-7293_584 was found in that previous report, under the name
PC-5p-263_4142, and it was the 23rd and 32nd most abundant among L3 and L4 secretions,
respectively. Similarly, PC-3p-5433_825 was found under the name PC-3p-955_1342 in the
previous paper [16], and it was the 24th and 26th most abundant in L3 and L4 secretions,
respectively. Both sequences were also released abundantly by mf, adult males, and females;
however, PC-3p-5433_825 was slightly more abundant in the secretions of L3 and L4 in
normalized count libraries (Table 2). However, these were not reported in the D. immitis
somatic miRNAome [19], and have so far not been reported in the secretions of other filarial
nematodes in vivo (in host blood). Sequence alignments with previously reported similar
sequences are shown in Figure 3.
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′
Figure 2. Venn diagram showing miRNAs common to datasets. Comparison of mature miRNA
sequences across L3 and L4 secretions with a previous study [16]. Both strains of the current study
were considered, as well as ‘low confidence’ sequences (e.g., not listed in miRBase), as they may
include novel sequences.
Table 2. Literature reportings of two predicted candidates in D. immitis and other filarial nematodes. Other filarial species








PC-5p-7293_584 Yes No No No
PC-3p-5433_825 Yes Yes No No
Figure 3. Sequence alignments of predicted candidates found in this study and previous reports.
Sequences described in the current study are indicated in bold and red. (A) Alignments with PC-5p-
7293_584. (B) Alignments with PC-3p-5433_825. Stars represent nucleotide matching positions in the
predicted mature sequence. PC-5p-263_4142 and PC-3p-955_1342 were detected in vitro [16], while
PC-3p-2144_333 and PC-3p-2034_418 were previously described in infected dogs (laboratory and
natural infections) [9].
In D. immitis-infected dog serum, bma-miR-87a_R+1 was the 9th most abundant [9]
and found in supernatants from all stages examined [16]. The sequence of PC-3p-5433_825
was found among the top 20 in dog serum as well (under the name PC-3p-2144_333), in a
pool of samples from laboratory infections (from both Missouri and MP3 strains), as well
as in a natural infection (under the name PC-3p-2034_418) [9] (Figure 3).
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2.4. Target Prediction in Host Genome and Overrepresentation Analysis
In an attempt to understand the biological significance of the extracellular presence of
these miRNAs in the canine host, computational target prediction within the dog transcrip-
tome was conducted. Target prediction informs on the putative biological functions that
D. immitis larvae may regulate in the dog by the secretion of miRNAs. Considering ‘high-
confidence’ miRNAs (Groups 1, 2a, 2b; see Materials and Methods and Supplementary
Table S1) and predicted candidates (Group 4), present in at least one sample in 10 copies or
more, 58 L3 miRNAs and 94 L4 miRNAs were used for a computational target prediction
within the dog genome, using the stand-alone TargetScan algorithm. Over 15,000 dog genes
appeared to be targeted by the selected miRNAs from each stage. Overrepresentation
analysis was used to identify the most significantly targeted host pathways within immune
functions. The top 5 enriched pathways based on FDR are listed in Table 3. There were 84
categories significantly enriched in the predicted targets of L3 miRNAs. Behind several
of the gene ontology (GO) descriptions are many fibroblast growth factor (FGF) isoforms,
FGF receptors, as well as forkhead box proteins, among many others (146 in total). There
were 64 categories significantly enriched in the predicted targets of L4 miRNAs. Gener-
ally, membrane transport features are predicted to be impacted by L4-secreted miRNAs.
Interestingly, MAPK cascade was found among the top enriched categories.
Table 3. Overrepresentation analysis (gene ontology, biological processes) of predicted dog targets of
D. immitis L3 and L4-derived miRNAs.
D. immitis L3 Gene Ontology—Biological Processes























1.94 × 10−7 0
D. immitis L4 Gene Ontology—Biological Processes














7.84 × 10−8 0




2.67× 10−11 4.45 × 10−8
3. Discussion
Our objective was to assess the consistency of the excretory/secretory miRNA profiles
of L3 and L4 of two D. immitis strains in vitro, despite their different macrocylic lactone
susceptibility status. Overall, we found a good agreement between the current study and
previously published data for D. immitis [16], although there was generally an even higher
agreement between L3 and L4 secretions from the same study, highlighting the impact
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of the inherent inter-experimental variation on resulting data. While the most abundant
miRNA species overlapped substantially, their relative rank varied slightly. Regardless of
the macrocyclic lactone susceptibility status of the two strains we have examined, our data
suggest that the strain involved will have little impact on the most abundantly secreted
miRNAs. There was not a dramatic impact of the two D. immitis laboratorial strains on the
miRNA species we found, as only two miRNAs were significantly differentially expressed
(bma-miR-228 and PC-5p-7293_584, by less than two-fold). Similarly, only four sequences
appeared differentially expressed between L3- and L4-derived material (bma-miR-87a_R+1,
bma-miR-5866, hpo-miR-10078-5p_1ss10TC, and asu-let-7-5p).
We have sequenced two candidate miRNA markers that are highly abundant and
consistently found in both stages and both strains of D. immitis assessed in the study,
but also that have been previously found in L3, L4, mf, and adults: PC-3p-5433_825
and PC-5p-7293_584. At the time of writing, these candidate markers did not have any
match in miRBase [20,21] or MirGeneDB 2.0 [22], and hence, have no known mammalian
orthologues. In addition, these sequences have not been detected in the secretions of other
filarial nematodes in vivo thus far. Therefore, we believe that these miRNAs are potentially
unique to D. immitis. The fact that these two predicted candidates have been found in the
secretions of different D. immitis strains and across several independent studies speaks in
favor of their actual existence (i.e., they are no artifacts). In addition, PC-3p-5433_825 was
also discovered in the blood of heartworm-infected dogs, as well as in all D. immitis stages
examined thus far [16]. The fact that both candidates were not detected in the somatic
miRNA fraction may be due to the different computational approaches to search for novel
miRNA candidates [19]. Both sequences were described in adult secretions in >100 copies;
the sequence similar to PC-5p-7293_584 (PC-5p-263_4142) was detected abundantly in
adult female supernatants (>1200 copies), however, with one base difference at the 5′ end.
Within the canine host, L3/L4-specific miRNAs may be detectable as early as 2 weeks
post-infection when L3s are molting to L4 in the subcutaneous tissues. However, it is
unknown if these would remain detectable after 60–70 days post-infection when most
L4s should have molted to the young adult stage (L5) and may be already present in
the pulmonary arteries and heart [6]. An important follow-up step will be to assess the
temporal changes of D. immitis-derived miRNA profiles in the biofluids of experimentally
infected dogs through the course of infection. This will allow us to start addressing potential
overlaps or discrepancies between in vitro and in vivo secretions; it is currently unclear how
well miRNA secretion profiles produced in vitro actually reflect in vivo ‘natural’ settings.
The detection of miRNA from L3 and L4 represents a challenge due to the small
nematode biomass they represent relative to host tissues, their unresolved localization
in the hosts’ organism, and their rapid development to the following developmental
stages. Nevertheless, nematode-derived miRNAs of related filarioid nematodes whose
neither adult nor larval stages reside in the hosts’ circulatory system have been detected
in biofluids. This has been the case for tissue-dwelling filarial nematodes, O. volvulus, O.
ochengi, and L. loa [11–13], all of which belong to the same family, Onchocercidae, as D.
immitis. Circulating miRNAs are believed to be either stabilized in protein complexes or
packaged in extracellular vesicles (e.g., in exosomes). In both cases, these miRNAs are
highly stable and protected from enzymatic degradation or pH incompatibilities—a good
characteristic for diagnostic biomarkers [23,24].
Lagatie and colleagues attempted to detect an array of O. volvulus-derived miRNAs
in biofluids of naturally infected humans [25]. They concluded that circulating parasite
miRNAs are not present at a sufficiently high level to be used as a biomarker for O.
volvulus infection or treatment monitoring using LNA-based RT-qPCR analysis, as only
some miRNAs showed detectable signals in some but not all samples [25]. While the
analysis relied on a maximum volume of 200 µL serum or plasma, we argue that larger
sample volumes may easily be acquired from dogs to be used for diagnosing D. immitis
infections. In a previous study, several ml of blood were collected from mf-circulating
mature D. immitis infections where dog serum had been processed for the detection of
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two D. immitis-specific miRNAs by RT-qPCR [9]. Custom-designed stem-loop RT-qPCR
protocols may prove highly efficient to discriminate highly similar miRNA sequences and
improve sensitivity [26]. While most studies on parasite-circulating miRNAs have focused
on cell-free biofluids, it may be necessary to include the surrounding cell populations (such
as phagocytes). In the Litomosoides sigmodontis mouse model, macrophages were shown
to represent a parasite miRNA-enriched in vivo reservoir [27]. Generally, there is a need
for comparative studies of miRNA profiles of different biofluids of dogs infected with D.
immitis, as it could help to determine the usefulness of different sample types.
Many immune-related dog pathways are predicted to be targeted by the D. immitis
L3 and L4 secreted array of miRNAs. These differ for L3 and L4 secretions and will be
worth exploring further for insight into the interactions of larval stages with the canine
host. Enriched GO terms resulting from L3 host target predictions revealed several pat-
tern specification processes, which are broader networks involved in cell and organism
differentiation and fate/commitment. Horizontal miRNA transfer from parasite to host
has been shown; miRNA-driven gene downregulation may have an obvious impact on the
host immune response among other fundamental biological processes [17,28,29]. Protein
deubiquitination is a conserved mechanism to rescue proteins from degradation or to end
ubiquitin signaling [30,31]. It is widely accepted that ubiquitination and deubiquitina-
tion are involved in various aspects of immune regulation, encompassing TCR signaling,
T cell differentiation, immune tolerance, and so forth [32]. The accumulating evidence
suggests potential interactions between so-called ‘immune checkpoint pathways’ and ubiq-
uitination/deubiquitination in disease, including in the context of infectious diseases, for
example, in bacterial or protozoal (Trypanosoma) infections [31,33]. Several members of
the fibroblast growth factor (FGF) and FGF receptor family, among others, are potential
targets of L3- and L4-derived miRNAs. These fulfill important roles in cell signaling and
in regulating the expression of genes involved in cell growth, proliferation, differentia-
tion, and longevity [34]. MAPKs are involved in various cellular responses, including
the production of proinflammatory cytokines or antigen presentation. In helminth infec-
tions, signaling through toll-like receptors is mediated through the MAPK cascade; MAPK
pathway and ERK1/2 activation support the induction of regulatory T cells/T helper 2
induction [8]. Some parasitic nematode-derived proteins, such as the Acanthocheilonema
viteae cystatin have been shown to act as negative regulators of MAPK via other molecules,
inducing regulatory responses [35]. Similarly, many bacterial pathogens have been shown
to target crucial branches of the MAPK signaling in order to put pressure on the host [36].
Overall, upon uptake by host cells, D. immitis-derived miRNAs have the potential to
modulate host immune responses, according to the current computational predictions.
These would require experimental validation of the predicted targets in order to represent
conclusive results.
4. Materials and Methods
4.1. Mosquito Rearing
For each mosquito cycle, only quality mosquito eggs of Aedes aegypti (Liverpool strain)
were selected to propagate consequent mosquito cycles in an environmental chamber. The
mosquito larvae were fed larvae food daily until pupation. The pupae were sorted by sex,
discarding roughly 80% of the males; the majority of the female pupae were placed into
rearing buckets.
4.2. D. immitis Infection for Obtaining L3s and L4s
The adult female mosquitoes were fed D. immitis-infected blood for a minimum of 2.5
h. The mosquitoes were dissected for L3 collection 14 days after blood feeding. The 2 D.
immitis strains used were Missouri-2005 (susceptible to macrocyclic lactones) and Yazoo-
2013 (resistant to macrocyclic lactones) [37,38]. These 2 strains were chosen to represent
the different macrocyclic lactone susceptibility and were based on their availability in
the laboratory.
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4.3. In Vitro Culturing of L3s and L4s
Batches of approximately 250 D. immitis L3s were washed a minimum of five times
with fresh RPMI to completely remove mosquito debris. Fresh culture media was added to
well plates and L3s were added into trans-well plates and incubated in a 5% CO2 incubator
at 37 ◦C. The supernatant was collected every 48 h for two weeks. The supernatant collected
on days 2 and 4 of culture were designated as L3-derived supernatants; those collected
on days 8 and 12 were L4-derived supernatants. After each supernatant collection, dead
L3/L4s were removed and new sterile media were added to the remaining live worms.
In total, there were 3 experimental replicates per larval stage and strain (Table 4). All
supernatant samples were stored at −80 ◦C until further processing.
Table 4. Experimental replicates and cultured larvae.








Total RNA was extracted from L3- and L4-derived supernatant of each strain, in
triplicate, using the Norgen plasma/serum RNA purification midi kit (Norgen Biotek Corp.,
Thorold, ON, Canada) [16]. The RNA was extracted from 1 mL of each supernatant sample,
eluted in 25 µL, and stored at −80 ◦C. To avoid cross-contamination, the supernatants of
2 different strains were never extracted alongside each other.
4.5. RNA Sequencing and Analysis
There were 6 samples from each strain, encompassing 3 replicates from L3 and 3 from
L4 (Table 4), submitted to miRNA deep sequencing. The sequence input for sequencing
was limited to the 18–30 nt size range. FastQC comprised a per-base sequence quality
assessment for each submitted sample (not shown). The general characteristics of the reads
(e.g., read length distribution) obtained for the different libraries were assessed by LC
Sciences. The raw data were filtered using a filter module in an in-house program to delete
low-quality reads, 3’ adapter sequences, and contaminations. The sequences ≥18 nt of clean
data were annotated in the Rfam database (http://www.sanger.ac.uk/software/Rfam) [39]
to remove non-coding RNA (rRNA, tRNA, snRNA, snoRNA) and degradation fragments
of mRNA. The remaining sequences were aligned against all nematode miRNAs listed
in miRbase (Release 21, http://www.miRbase.org) [20,21]; perfectly matched sequences
were considered conserved D. immitis miRNAs. Nematode species, for which miRNAs are
available in miRNAse, are the following: Brugia malayi, Ascaris suum, Haemonchus contortus,
Heligmosomoides polygyrus, Strongyloides ratti, Caenorhabditis elegans, C. briggsae, C. brenneri, C.
remanei, Pristionchus pacificus, and Panagrellus redivivus. Reads were then assigned to groups
reflecting the confidence level that these sequences are truly D. immitis miRNAs. These
groups are based on genome mapping properties, secondary structure, and homology to
known miRNAs. Group 1: the reads were mapped to miRNAs/pre-miRNAs of specific
species in miRbase, and the pre-miRNAs were further mapped to a genome and EST;
Group 2a: the reads were mapped to miRNAs/pre-miRNAs of selected species in miRbase,
and the mapped pre-miRNAs were not further mapped to a genome, but the reads (and, of
course, the miRNAs of the pre-miRNAs) were mapped to a genome. The extended genome
sequences from the genome loci may form hairpins; Group 2b: the reads were mapped to
miRNAs/pre-miRNAs of selected species in miRbase and the mapped pre-miRNAs were
not further mapped to a genome, but the reads (and, of course, the miRNAs of the pre-
miRNAs) were mapped to a genome. The extended genome sequences from the genome
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loci may not form hairpins; Group 3: the reads were mapped to miRNAs/pre-miRNAs of
selected species in miRbase and the mapped pre-miRNAs were not further mapped to a
genome, and the reads were not mapped to a genome, either, but the reads were mapped
to the mature miRNAs; Group 4 (predicted candidates): the reads were not mapped to
pre-miRNAs of selected species in miRbase, but the reads were mapped to a genome, and
the extended genome sequences from the genome may form hairpins. The normalization
of sequence counts from each sample (or dataset) was achieved by dividing the counts by a
library size parameter of the corresponding sample. The library size parameter is a median
value of the ratio between the counts of a specific sample and a pseudo-reference sample.
A count number in the pseudo-reference sample is the count geometric mean across all
samples (see [16]).
4.6. Predicted miRNA Targets and Pathway Enrichment
miRNA target prediction was performed using the standalone TargetScan software
package v. 7 (http://www.targetscan.org) [40], implemented as a standalone workflow
under iPortal [41] and openBIS [42], using default parameters. All host genes that were
targeted at least twice, regardless of the context scores, were used in enrichment analyses.
The R version of the WEB-based Gene SeT Analysis Toolkit (WebGestalt) [43,44] was
employed for overrepresentation analysis (ORA) based on gene ontology “biological
processes” [45], using default parameters, with FDR < 0.05. As a reference gene list, we
employed the immunological signatures (collection C7) from the Molecular Signatures
Database v 6.2 (Gene Set Enrichment Analysis database, http://software.broadinstitute.
org/gsea/msigdb/index.jsp) [46,47].
5. Conclusions
Mature miRNA sequences shed by L3 and L4 overlapped largely, both qualitatively
and quantitatively. Similarly, the laboratorial D. immitis strain did not significantly impact
the excretory/secretory miRNA profile in vitro, regardless of their macrocyclic lactone
susceptibility status. The presence and temporal expression of the candidate miRNA
biomarkers in vivo in biofluids of the canine host should be further investigated. The
potential of L3- and L4-specific sequences as biomarkers of early heartworm infection
remains to be assessed and validated in vivo using samples derived from experimentally
and naturally infected dogs. Nevertheless, there are challenges associated with the limited
biomass of such larval stages and sensitivity issues of the currently available miRNA
detection assays.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pathogens10070786/s1: Table S1. miRNAs shed by two D. immitis strains, L3 and L4 stages
in vitro; Table S2. miRNAs shed by D. immitis L3 in vitro (stratified by strain); Table S3. miRNAs
shed by D. immitis L4 in vitro (stratified by strain); Table S4. miRNAs shed by D. immitis strain Yazoo
in vitro (stratified by stage); Table S5. miRNAs shed by D. immitis strain Missouri in vitro (stratified
by stage).
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